Ribavirin treatment in M4/M5 acute myeloid leukemia patients

Thanks to the support of The Leukemia and Lymphoma Society (USA), a Canada-wide Phase I/II clinical trial will be carried out to monitor the use of Ribavirin as a novel therapy in the treatment of M4/M5 acute myeloid leukemia patients. This trial stems from pre-clinical studies indicating that Ribavirin suppresses the activities of a cellular factor, eIF4E, which is involved in making cells cancerous.

The study team is led by Dr Katherine Borden at the Institute for Research in Immunology and Cancer (IRIC) at the Université de Montréal and involves several sites throughout Canada. The clinical trial will be managed from the Clinical Research Unit at the Jewish General Hospital, a McGill University affiliated Hospital.  For more information about the trial please contact Dr Effie Cocolakis, the study coordinator (ecocolakis@jgh.mcgill.ca)